Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TranspoCART19 phase I/IIa study in relapsed or refractory B-cell lymphoma
2024-514544-90-00Phase 2Authorised
- Sponsor
- Fundación de Investigación Biomédica de Salamanca
- Start
- Oct 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TranspoCART19 in mature B-cell lymphoma, sponsored by Fundación de Investigación Biomédica de Salamanca. Primary endpoints: Recommended phase II dose and safety and Best response rate within 3 months. Planned start Oct 2024; status: authorised.
02
Drugs
TranspoCART19
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2024-514544-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514544-90-00.